Cargando…

Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke

AIM: To study the diagnostic and prognostic role of serum galectin-1 (Gal-1) and -3 (Gal-3) in acute ischemic stroke (AIS) patients. METHODS: We enrolled 233 patients with first-ever acute ischemic stroke and 252 healthy controls in this study. The AIS severity was evaluated by National Institutes o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Han, Wang, Zhi-Hao, Zhang, Na, Liu, Si-Da, Zhao, Jian-Jun, Liu, Song-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752558/
https://www.ncbi.nlm.nih.gov/pubmed/29312645
http://dx.doi.org/10.18632/oncotarget.18211
_version_ 1783290131781779456
author Dong, Han
Wang, Zhi-Hao
Zhang, Na
Liu, Si-Da
Zhao, Jian-Jun
Liu, Song-Yan
author_facet Dong, Han
Wang, Zhi-Hao
Zhang, Na
Liu, Si-Da
Zhao, Jian-Jun
Liu, Song-Yan
author_sort Dong, Han
collection PubMed
description AIM: To study the diagnostic and prognostic role of serum galectin-1 (Gal-1) and -3 (Gal-3) in acute ischemic stroke (AIS) patients. METHODS: We enrolled 233 patients with first-ever acute ischemic stroke and 252 healthy controls in this study. The AIS severity was evaluated by National Institutes of Health Stroke Scale (NIHSS) scores. The serum Gal-1 and -3 levels were determined. All patients were followed for 1 years and the functional outcome were evaluated by modified Rankin Scale (mRS) scores. RESULTS: We found that AIS patients had higher serum Gal-1 and -3 levels than controls. The serum Gal-3 level was closely associated with the AIS severity indicated by NHSS and infarction volume. Serum Gal-3 levels were significantly higher in patients with a poor outcome indicated by mRS scores than those in patients with a good outcome. In contrast, the serum Gal-1 is not associated with the severity and outcome of acute AIS patients. Our in vitro studies show that Gal-3 knockdown with siRNA dramatically increased the culture neuron cell viability and reduced apoptosis under oxygen glucose deprivation treatment. Meanwhile, the pro-inflammatory cytokine expression decreased with the inhibition of Gal-3. CONCLUSION: Our finding provides a novel biological marker, serum Gal-3, for monitor of acute AIS patients.
format Online
Article
Text
id pubmed-5752558
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57525582018-01-08 Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke Dong, Han Wang, Zhi-Hao Zhang, Na Liu, Si-Da Zhao, Jian-Jun Liu, Song-Yan Oncotarget Clinical Research Paper AIM: To study the diagnostic and prognostic role of serum galectin-1 (Gal-1) and -3 (Gal-3) in acute ischemic stroke (AIS) patients. METHODS: We enrolled 233 patients with first-ever acute ischemic stroke and 252 healthy controls in this study. The AIS severity was evaluated by National Institutes of Health Stroke Scale (NIHSS) scores. The serum Gal-1 and -3 levels were determined. All patients were followed for 1 years and the functional outcome were evaluated by modified Rankin Scale (mRS) scores. RESULTS: We found that AIS patients had higher serum Gal-1 and -3 levels than controls. The serum Gal-3 level was closely associated with the AIS severity indicated by NHSS and infarction volume. Serum Gal-3 levels were significantly higher in patients with a poor outcome indicated by mRS scores than those in patients with a good outcome. In contrast, the serum Gal-1 is not associated with the severity and outcome of acute AIS patients. Our in vitro studies show that Gal-3 knockdown with siRNA dramatically increased the culture neuron cell viability and reduced apoptosis under oxygen glucose deprivation treatment. Meanwhile, the pro-inflammatory cytokine expression decreased with the inhibition of Gal-3. CONCLUSION: Our finding provides a novel biological marker, serum Gal-3, for monitor of acute AIS patients. Impact Journals LLC 2017-05-25 /pmc/articles/PMC5752558/ /pubmed/29312645 http://dx.doi.org/10.18632/oncotarget.18211 Text en Copyright: © 2017 Dong et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Dong, Han
Wang, Zhi-Hao
Zhang, Na
Liu, Si-Da
Zhao, Jian-Jun
Liu, Song-Yan
Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke
title Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke
title_full Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke
title_fullStr Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke
title_full_unstemmed Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke
title_short Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke
title_sort serum galectin-3 level, not galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752558/
https://www.ncbi.nlm.nih.gov/pubmed/29312645
http://dx.doi.org/10.18632/oncotarget.18211
work_keys_str_mv AT donghan serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke
AT wangzhihao serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke
AT zhangna serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke
AT liusida serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke
AT zhaojianjun serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke
AT liusongyan serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke